Evidence map›Paper›PMID 27927769›Full record

ArticleHaematologica2017

Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of

Chiara Cavallini, Carlo Visco, Santosh Putta, Davide Rossi, Elda Mimiola, Norman Purvis, Ornella Lovato, Omar Perbellini, Erika Falisi, Monica Facco and 8 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.Hematology. American Society of Hematology. Education Program · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 3 countries.

Chiara CavalliniResearch Center LURM, University of Verona, Italy.
Carlo ViscoDepartment of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.
Santosh PuttaQognit Inc., Foster City, CA, USA.
Davide RossiHematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.
Elda MimiolaDepartment of Medicine, Section of Hematology, University of Verona, Italy.
Norman PurvisPierian Biosciences, Franklin, TN, USA.
Ornella LovatoResearch Center LURM, University of Verona, Italy.
Omar PerbelliniDepartment of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.
Erika FalisiDepartment of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.
Monica FaccoDepartment of Medicine, Hematology and Clinical Immunology Branch, University of Padua, Italy.
Livio TrentinDepartment of Medicine, Hematology and Clinical Immunology Branch, University of Padua, Italy.
Maria G RomanelliDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Italy.
Gianpietro SemenzatoDepartment of Medicine, Hematology and Clinical Immunology Branch, University of Padua, Italy.
Achille AmbrosettiDepartment of Medicine, Section of Hematology, University of Verona, Italy.
Gianluca GaidanoDepartment of Translational Medicine, Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Giovanni PizzoloDepartment of Medicine, Section of Hematology, University of Verona, Italy.
Alessandra CesanoNanoString, Inc, Seattle, WA, USA.
Maria T ScupoliResearch Center LURM, University of Verona, Italy mariateresa.scupoli@univr.it.
University of Verona · ITOspedale San Bortolo · ITUniversity of Padua · ITInstitute of Oncology Research · CHNanostring Technologies (United States) · USPierian Biosciences (United States) · USUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene Expression Regulation, LeukemicADP-ribosyl Cyclase 1Disease ProgressionHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionLeukemia, Lymphocytic, Chronic, B-CellMembrane GlycoproteinsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3MutationPhosphoproteinsPhosphorylationPrognosisReceptor, Notch1Receptors, Antigen, B-CellADP-ribosyl Cyclase 1CD38 protein, humanImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionMAPK1 protein, humanMembrane GlycoproteinsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NOTCH1 protein, humanPhosphoproteinsReceptor, Notch1Receptors, Antigen, B-CellRNA Splicing FactorsSF3B1 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID27927769
PMCPMC5395127
OpenAlexW2559913144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.